The research, led by Gui-Ming Zhang, Le Yu and colleagues at Southern Medical University and collaborating institutions in China, took a deliberately indirect route. Rather than trying to block the oncogenic signal at its source, the team asked a different question: which genes does a cancer cell become fatally dependent on once GNAQ has been mutated? This concept, known as synthetic lethality, exploits the idea that a mutation that is harmless on its own can become lethal when a second, compensating function is removed. In practice, it means that a drug targeting the partner vulnerability can kill cancer cells while sparing normal tissue, which lacks the initiating mutation.

To find such vulnerabilities systematically, the researchers used an isogenic CRISPR screening approach. They engineered pairs of cell lines that were genetically identical except for the presence or absence of oncogenic GNAQ signaling, and then used CRISPR-based gene knockout across the genome to see which losses were selectively catastrophic only in the mutant cells. This design filters out genes that are generally essential for all cells and isolates those whose importance is specifically created by the cancer-driving mutation. Among the top-ranked hits, one gene stood out: EP300, which encodes p300, a protein lysine acetyltransferase that decorates histones and other proteins with acetyl groups to regulate gene expression.

Notably, the screen also flagged CREBBP, the gene encoding CBP, a closely related paralogue of p300 that shares much of its catalytic machinery and often partners with it at regulatory DNA. The convergence of both paralogues near the top of the candidate list suggested that the dependency was not a screening artifact but a genuine, redundant axis that GNAQ-mutant cells rely upon. Because p300 and CBP sit at the interface between signaling pathways and the epigenetic machinery that executes gene expression programs, their identification pointed the investigators toward a specific mechanism worth dissecting in detail.

That mechanism turned out to involve YAP, the transcriptional co-activator that serves as the main effector of the Hippo signaling pathway. When the Hippo pathway is switched off, YAP accumulates in the nucleus and teams up with DNA-binding transcription factors to activate genes promoting cell growth, survival and migration. Oncogenic Gαq is known to feed into this pathway, driving unrestrained YAP activity in uveal melanoma. The new work shows that p300 and CBP are not passive bystanders in this process: they physically interact with YAP at chromatin, the packaged form of DNA inside the nucleus, and this interaction is what allows the YAP program to be fully executed.

At the chromatin level, the researchers found that p300 and CBP enhance the acetylation of histone H3 at lysine 27, a chemical mark abbreviated H3K27ac that flags active promoters and putative enhancers, the regulatory regions that boost gene transcription. In GNAQ-mutant cells, this acetylation is concentrated at the regulatory elements of YAP target genes. The histone mark, in turn, promotes the recruitment of RNA polymerase II, the enzyme that reads genes into messenger RNA, together with CDK9, a kinase that helps release the paused polymerase into productive elongation. In other words, p300 and CBP act as the chromatin-level engine that converts YAP’s presence at DNA into actual gene output, and without them the oncogenic transcriptional program stalls.

The functional consequences of this dependency were tested rigorously in animal models. The team employed multiple in vivo models representing clinically relevant stages of Gαq-mutant uveal melanoma, from primary tumor growth to metastatic spread, the stage that matters most for patient survival. Both genetic approaches, which remove p300 function directly, and pharmacological inhibitors of its acetyltransferase activity profoundly impaired tumor growth and metastasis in these models. The consistency between genetic and drug-based suppression strengthens the case that the effect is genuinely mediated by p300’s enzymatic function rather than some scaffolding role or off-target toxicity, and it provides a direct preclinical rationale for moving toward therapeutic inhibition.

The significance of the finding lies in its strategic positioning. Because the dependency is created by the oncogenic Gαq pathway itself, p300 inhibition represents a form of indirect targeting: the drug does not need to shut down the mutated G protein, which has proved chemically difficult, but instead blocks an essential downstream enabler of the cancer’s transcriptional addiction. Epigenetic enzymes such as p300 and CBP are increasingly considered druggable, and small-molecule acetyltransferase inhibitors are an active area of medicinal chemistry. The study thereby converts a hard-to-drug oncogene problem into a potentially tractable epigenetic one, a reframing that could reshape how the field approaches GNAQ- and GNA11-driven cancers more broadly.

There are, of course, caveats that temper immediate clinical translation. p300 and CBP perform essential functions in many normal cell types, including roles in hematopoiesis and general transcriptional regulation, so therapeutic windows will need to be carefully defined, and the authors note that their work establishes p300 as a potential therapeutic target rather than a validated drug. The pharmacological results come from preclinical models, and the behavior of human metastatic disease in patients may introduce additional dependencies and resistances not captured in the laboratory. Nonetheless, the synthetic lethal logic demonstrated here, in which the very mutation that drives the cancer also creates its Achilles’ heel, is exactly the kind of therapeutic principle that has succeeded in other hard-to-treat tumors, such as PARP inhibition in BRCA-mutant breast and ovarian cancers.

For patients with metastatic uveal melanoma, whose median survival has remained dismal for decades, the study offers something the field has lacked: a mechanistically grounded, experimentally validated vulnerability that is specific to the molecular engine of their disease. By showing that GNAQ-mutant tumors depend on the p300/CBP chromatin machinery to sustain YAP-driven transcription, the researchers have charted a path from genome-wide screening to a defined mechanism to in vivo efficacy. The next steps, developing or deploying clinically suitable acetyltransferase inhibitors and testing them in appropriately designed trials, will determine whether this laboratory insight can be converted into a real therapeutic option for one of oncology’s most neglected cancers.

Subject of Research: Synthetic lethal identification of p300/CBP as a therapeutic vulnerability in GNAQ-mutant uveal melanoma

Article Title: Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas

Article References: Zhang, G.-M., Yuan, J., Chen, L., Jin, X.-Y., Ren, Z.-L., Zhou, Y.-L., Zhou, R., Xiao, Y.-F., Wang, J.-W., Zhang, X.-A., Bai, C., Li, Z., Li, Y.-L., & Yu, L. (2026). Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas. Nature Communications. https://doi.org/10.1038/s41467-026-77999-8

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77999-8

Keywords: uveal melanoma, GNAQ, p300, CBP, YAP, synthetic lethality, CRISPR screen, epigenetics, H3K27 acetylation, Hippo pathway, targeted therapy, eye cancer

The work, published in Nature by a team led by Marius Wernig, tackles a long-standing bottleneck in the field of microglia replacement. Microglia are the brain’s own macrophages, and in several devastating genetic disorders they carry the same disease-causing mutations as the rest of the body. Over the past two decades, researchers have shown that hematopoietic stem and progenitor cell transplantation can repopulate the brain with donor-derived, microglia-like cells, effectively swapping out a diseased brain immune system for a healthy one. Recent studies have demonstrated that this strategy can correct deficiencies in mouse models of conditions ranging from lysosomal storage diseases to Alzheimer’s-related pathology, and clinical momentum has been building.

Yet a fundamental question has remained unanswered: which molecules inside a blood stem cell tell it to become a brain-bound myeloid cell rather than a red blood cell, a platelet, or a lymphocyte? The answer has been elusive largely because primary hematopoietic stem cells are vanishingly rare, making large-scale genetic experiments practically impossible. A typical mouse yields only a handful of true long-term repopulating stem cells, nowhere near enough for the tens of thousands of parallel gene perturbations a modern CRISPR screen demands.

The Stanford team circumvented this obstacle with a clever twist. They used cultured hematopoietic stem and progenitor cells, or cHSPCs, which can be expanded ex vivo using protocols originally developed for non-conditioned transplantation. The researchers established that these cultured cells retain two critical abilities: they can be genetically manipulated with CRISPR tools, and after transplantation they can differentiate into myeloid cells and repopulate the microglial niches of the brain. In other words, the expansion process does not destroy the properties that matter most for brain cell therapy.

With a workable cell source in hand, the team needed a way to watch myeloid differentiation happen in a dish. They found it in an unexpected place: primary neonatal astrocytes, the star-shaped support cells of the brain, carried strong signals capable of inducing myeloid specification of the cultured stem cells in vitro. When the stem cells were plated onto these astrocyte feeder layers, they proliferated, extended processes, and matured into cells that closely resembled brain myeloid cells. This co-culture system gave the researchers a controllable, scalable window into a process that normally unfolds deep inside living tissue.

That window opened onto an unprecedented genetic survey. The team screened roughly 20,000 individual genetic perturbations in the primary hematopoietic progenitors, asking which genes, when disabled, blocked or boosted the glia-induced transformation into myeloid cells. The screen returned genes involved in cell signalling, cell cycle control, mitochondrial function, and protein translation, painting a broad molecular portrait of the differentiation program. Among the hits, one gene stood out: Elp1, a subunit of the elongator acetyltransferase complex.

Elp1 is not an obscure player. The elongator complex helps modify transfer RNAs, a step that fine-tunes how efficiently particular codons are translated into protein, and mutations in Elp1 cause familial dysautonomia, a severe hereditary disorder of the autonomic and sensory nervous systems. Elongator mutations have also been linked to medulloblastoma and other neurodevelopmental syndromes. The new study adds an unexpected chapter to that story: Elp1 appears to suppress the unfolded protein response during myeloid specification. When Elp1 was knocked out, differentiating cells mounted a stress response from the endoplasmic reticulum, the cellular compartment where newly made proteins fold into shape, and the cells failed to generate myeloid progeny efficiently.

Crucially, the team showed that Elp1 is essential for the generation but not the maintenance of myeloid cells. In transplantation experiments, loss of Elp1 impaired the ability of donor cells to seed the brain with new myeloid populations, yet myeloid cells that had already differentiated and engrafted could survive after Elp1 was deleted later. This temporal distinction matters therapeutically: it suggests that the gene’s role is confined to a vulnerable window early in differentiation, and that established brain myeloid cells do not continuously require it. The researchers also confirmed the finding in human cells, showing that ELP1 knockout in human cord blood CD34-positive cells impaired myeloid repopulation in astrocyte co-cultures, indicating the mechanism is conserved across species.

Beyond the biology of a single gene, the study delivers a platform. By proving that expanded cultured stem cells can serve as a substrate for unbiased genetic interrogation of brain myeloid differentiation, the researchers have created a tool that others can use to systematically map the molecular logic of brain immune cell formation. The datasets generated in the study, including mouse sequencing data deposited in the Gene Expression Omnibus and proteomic data in the ProteomeXchange repository, are publicly available, lowering the barrier for follow-up work. The screen’s catalog of regulators, spanning signalling, cell cycle, mitochondrial function, and translation, provides a rich starting list for anyone seeking to improve the efficiency of microglia replacement.

The implications reach toward the clinic. If brain cell therapies based on hematopoietic transplantation are to become reliable treatments, researchers will need to understand and possibly engineer the differentiation program that donor cells follow. Knowing that Elp1 guards differentiating myeloid cells against proteotoxic stress suggests that manipulating this pathway, perhaps pharmacologically, could boost engraftment efficiency or protect engineered cells during the stressful journey from culture dish to brain parenchyma. It also raises a caution: any genetic engineering of donor stem cells must preserve Elp1 function, or the therapy may fail before it begins. As microglia replacement moves closer to human trials for diseases that currently have few options, this study supplies both a warning and a roadmap, revealing one of the molecular switches that determines whether transplanted blood stem cells can truly rebuild the brain’s immune defenses.

Subject of Research: Role of the Elp1 gene in hematopoietic stem cell myeloid differentiation and brain microglia repopulation

Article Title: Elp1 is required for myeloid differentiation and brain repopulation

Article References: Mader, M. M.-D., Li, W., Scavetti, A., Yoo, Y., Neumayer, G., Han, K., Shibuya, Y., Haney, M., Wyss-Coray, T., George, L., Lefcort, F., Bassik, M., Nakauchi, H., Wilkinson, A. C., & Wernig, M. (2026). Elp1 is required for myeloid differentiation and brain repopulation. Nature. https://doi.org/10.1038/s41586-026-11112-3

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11112-3

Keywords: Elp1, microglia replacement, hematopoietic stem cells, CRISPR screen, myeloid differentiation, unfolded protein response, elongator complex, neuroimmunology, astrocytes, cell therapy, familial dysautonomia, brain repopulation

The study, published in the journal Cancer Immunology Research, a journal of the American Association for Cancer Research, used a powerful genetic screening technique called a genome-wide CRISPR screen to systematically search for the genes involved in T-cell exhaustion. The research team, led by senior author Dr. Antoni Ribas, professor of medicine at the David Geffen School of Medicine at UCLA and director of the cancer center’s Tumor Immunology & Immunotherapy Program, focused on human CD8+ T cells engineered to recognize a melanoma antigen. By turning off thousands of genes one by one and repeatedly exposing the engineered T cells to tumor cells in a laboratory system designed to mimic the chronic tumor exposure seen in patients with solid tumors, the investigators were able to pinpoint which genetic changes helped the immune cells remain functional, active and capable of killing cancer cells during repeated encounters with their targets.

Justin Saco, a graduate student in the Ribas laboratory and first author of the study, explained that the experimental design was a critical part of the discovery. Instead of studying short-term T-cell activation, the team modeled the chronic, repeated tumor exposure that T cells experience in solid tumors. This repeated tumor rechallenge system allowed the researchers to identify regulators of long-term persistence and exhaustion more effectively than conventional approaches. Saco noted that immunotherapy depends on T cells staying active long enough to continuously recognize and kill cancer cells, and that if they lose function too early, tumors can grow back or escape immune control. The longer T cells remain functional, the better the chance of durable cancer control.

The screening process revealed a strong and consistent signal pointing to a protein-regulating pathway known as the Cullin-5 RING E3 ligase complex, or CRL5. This molecular machinery helps control how cells break down and recycle proteins, a fundamental process that influences many aspects of cellular behavior. Importantly, the signal was not limited to a single gene. Several different components of the CRL5 machinery were independently enriched across experiments and time points, a pattern that often suggests a biologically important pathway rather than a statistical fluke. This convergence of evidence from multiple independent components of the same complex gave the researchers confidence that CRL5 plays a central role in driving T-cell exhaustion.

When the researchers disrupted CRL5-related genes, the modified T cells maintained stronger tumor-killing ability, produced higher levels of immune signaling molecules, showed fewer molecular signs of exhaustion and preserved gene programs linked to survival and long-term immune function. In other words, silencing this pathway helped the engineered immune cells resist the gradual loss of function that normally occurs during chronic tumor exposure. The modified T cells stayed active longer, produced stronger anti-tumor responses and retained the molecular characteristics of functional, persistent killer cells rather than exhausted ones.

The team also tested a drug called MLN4924, which blocks the activation of Cullin-RING ligases, including CRL5. The drug partially reproduced the effects seen with genetic deletion, helping T cells maintain stronger long-term function in laboratory experiments. This pharmacological validation is significant because it suggests that the pathway could potentially be targeted with drugs rather than requiring genetic modification of the immune cells. In mouse models of human melanoma, animals treated with CRL5-deficient T cells showed improved tumor control compared with those receiving standard engineered immune cells, providing preclinical evidence that targeting this pathway could translate into better anti-tumor responses in living organisms.

The findings suggest that targeting the CRL5 pathway could potentially help improve the durability and effectiveness of T-cell-based immunotherapies for patients with solid tumors. By reducing a key biological mechanism that drives T-cell exhaustion, it may be possible to help immune cells stay active longer and maintain their cancer-fighting ability, potentially leading to stronger and more sustained treatment responses. This could be especially valuable for CAR T-cell therapies and other forms of adoptive cell therapy, which often struggle to remain effective over time in solid tumors where the immune cells are exposed to persistent tumor signals.

A companion research article by the research group of Dr. Julia Carnevale of the University of California, San Francisco provides additional support for the findings and for the broader potential of targeting molecular mechanisms of T-cell exhaustion to improve cancer immunotherapy. The convergence of evidence from two independent research groups strengthens the case that the CRL5 pathway is a biologically important regulator of T-cell persistence and that interfering with it could open new avenues for therapeutic development.

The study’s senior author, Dr. Antoni Ribas, is also the director of the Parker Institute for Cancer Immunotherapy Center at UCLA and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Other UCLA authors include Daniel Karin, J.J. Patten, Yichen Fan, Egmidio Medina, Nataly Naser Al Deen, Ameya Champhekar, Katie Campbell and Cristina Puig-Saus. The research was funded in part by the Parker Institute for Cancer Immunotherapy, the National Institutes of Health and philanthropic support. As the field of cancer immunotherapy continues to evolve, discoveries like this one highlight the importance of understanding the fundamental molecular mechanisms that govern immune cell function, and they point toward new strategies for engineering longer-lasting, more effective treatments for patients with solid tumors.

Subject of Research: A UCLA study identifies the Cullin-5 RING E3 ligase complex as a driver of T-cell exhaustion and shows that blocking it improves the persistence and anti-tumor function of engineered immune cells in preclinical models.

Article Title: UCLA researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy

Article References: UCLA researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: T-cell exhaustion, Cancer immunotherapy, CAR T-cell therapy, CRISPR screen, CRL5, Cullin-RING ligase, Solid tumors, Melanoma, Adoptive cell therapy, Cancer Immunology Research, UCLA, MLN4924

The research team, led by investigators at the Chinese PLA General Hospital, began with an unbiased hunt rather than a hypothesis. Using a customized CRISPR-Cas9 library targeting 1,649 metabolic enzymes and regulators—6,596 guide RNAs plus controls—they systematically disabled each gene in A498 clear cell renal cell carcinoma cells and tracked which losses crippled proliferation over 21 days. TPI1 emerged as one of the most robustly depleted hits, sitting at a hub position among the top ten negatively selected genes. The finding was more than a screening artifact: tissue microarrays built from 234 renal tumors and 172 adjacent normal specimens showed markedly elevated TPI1 protein in cancer tissue, a result corroborated by data from the TCGA and an independent cohort. TPI1 expression even climbed with tumor grade, alongside rising frequencies of gain-of-function alterations.

To confirm that TPI1 truly drives tumor growth, the researchers shut it down with short hairpin RNAs in renal cancer cells and watched proliferation collapse in growth curves, EdU incorporation assays, and colony formation tests. In mice bearing xenografts of TPI1-deficient OS-RC-2 cells, tumors were significantly smaller and lighter, with reduced Ki67 staining marking the slowdown in cell division. Crucially, deleting TPI1 caused DHAP to pile up inside cells to roughly ten times normal levels. When the team replaced endogenous TPI1 with a wild-type copy, growth recovered; when they substituted a catalytically dead K14M mutant that cannot handle DHAP, it did not. The lesson was unambiguous: it is TPI1’s enzymatic activity, not some scaffold function, that cancer cells depend on.

Because DHAP cannot cross cell membranes and no eukaryotic transporter for it is known, the team exploited a clever chemical workaround. They fed cells dihydroxyacetone, a membrane-permeable precursor that is converted intracellularly into DHAP by the enzyme TKFC. Supplementing with dihydroxyacetone suppressed cell viability, and silencing TKFC blunted that toxicity—direct evidence that the accumulating upstream metabolite, rather than the loss of the downstream product GAP, was doing the damage. Indeed, adding GAP itself to TPI1-deficient cells offered no rescue at all. The experiment repositioned DHAP in the scientific imagination: no longer a passive glycolytic intermediate, but a molecule with signaling consequences, echoing recent work showing that DHAP can inform the nutrient-sensing complex mTORC1 about glucose availability.

What actually happens inside a cell drowning in DHAP turned out to be the study’s most striking revelation. Transcriptome sequencing of TPI1-deficient cells showed positive enrichment of inflammatory signaling, the p53 pathway, and a senescence-associated secretory phenotype gene set, alongside suppression of E2F targets and G2/M checkpoint programs. The cells stained positive for senescence-associated beta-galactosidase, accumulated the DNA damage marker gamma-H2AX, activated the p53-p21 axis, lost Lamin B1 from their nuclear envelopes, and arrested in the G0/G1 phase. Luminex multiplex analysis and ELISA confirmed a flood of inflammatory secretions—IL-6, IL-8, TNF-alpha, and GM-CSF—the classic SASP signature. In xenografted tumors, the same markers rose in tissue sections. This was not cell death; it was cellular senescence, a durable proliferative arrest that oncologists have long hoped to impose on tumors deliberately.

The engine behind that arrest was mitochondrial. TPI1 knockdown sharply increased overall reactive oxygen species, and probes specific for mitochondrial superoxide and hydrogen peroxide showed the origin clearly: mitochondrial ROS surged. A mitochondria-targeted antioxidant, Mito-TEMPO, brought intracellular ROS back down, reduced the fraction of beta-galactosidase-positive cells, and lowered gamma-H2AX, p53, and p21—mimicking the effects of the general antioxidant NAC. Mitochondrial oxidants were therefore acting as the critical effector, converting a metabolic glitch into DNA double-strand damage and, ultimately, senescence. The remaining question was what had switched the mitochondria into this overdrive state in the first place.

Integrated metabolomic and transcriptomic analysis pointed to calcium. TPI1-deficient cells showed elevated intracellular calcium by both colorimetric assay and fluorescent imaging with Fluo-4 AM. When the researchers compared two chelators, the result was decisive: BAPTA-AM, which binds calcium inside the cell, rescued viability and dampened senescence markers, SASP secretion, and DNA damage, while EGTA, which only chelates extracellular calcium, did essentially nothing. In living tumors, peritumoral BAPTA-AM injections let TPI1-deficient xenografts grow significantly faster than vehicle-treated controls. The signal itself proved to be cyclic ADP-ribose, or cADPR, a second messenger that opens ryanodine receptors on the endoplasmic reticulum and liberates calcium into the cytosol. Metabolomics revealed cADPR accumulating after TPI1 loss, and providing cADPR directly to healthy cells was sufficient on its own to induce calcium overload, beta-galactosidase activity, DNA damage, p53-p21 activation, and SASP release—all of which BAPTA-AM reversed. Conversely, blocking cADPR signaling with the antagonist 8-Br-cADPR suppressed the calcium rise and the senescence program triggered by TPI1 depletion.

Upstream of cADPR, the team identified an unexpected culprit: SARM1, a sterile alpha and TIR motif containing protein long known for its role in axonal degeneration and increasingly appreciated as an NAD-consuming enzyme with catalytic activity rivaling the classical ADP-ribosyl cyclase CD38. In TPI1-deficient cells, CD38 was undetectable, but SARM1 rose markedly—dihydroxyacetone treatment produced the same effect. Overexpressing SARM1 alone reproduced the entire phenotype, from gamma-H2AX and p53-p21 induction to Lamin B1 loss, ROS generation, and SASP secretion, while suppressing proliferation and clonogenic capacity. Removing SARM1 from TPI1-deficient cells restored viability, normalized calcium and cADPR levels, reversed the DNA damage and redox stress, and let xenografts grow faster in mice. Notably, mTORC1 appeared to feed into this circuit: TPI1 loss activated the pathway, read out through phospho-S6K1, and the mTORC1 inhibitor rapamycin attenuated SARM1 induction—yet forced SARM1 expression still drove senescence signaling even under rapamycin, placing SARM1 centrally in the cascade with mTORC1 as a modulator.

The mechanism appears to travel well beyond kidney cancer. Knocking down TPI1 in prostate cancer C4-2, lung cancer A549, and bladder cancer T24 cells likewise curbed viability, raised beta-galactosidase activity, elevated SARM1 and gamma-H2AX, depleted Lamin B1, and increased IL-6, IL-8, and TNF secretion, with TPI1-deficient bladder cancer xenografts growing more slowly in mice. In each line, cADPR and calcium climbed after TPI1 loss, and both BAPTA-AM and 8-Br-cADPR blunted the senescence phenotype, as did SARM1 knockdown—a conserved SARM1-cADPR-calcium axis operating across tumor types.

The implications cut in two directions. For patients with TPI1 deficiency, the rare autosomal recessive disorder caused most often by the E104D mutation, the study offers a mechanistic clue: neither patients nor fly models show overt ATP depletion, and the new work suggests their hemolytic anemia and neurodegeneration may instead stem from a redox-calcium pathway in which DHAP overload drives mitochondrial oxidant stress. For oncology, the findings sketch a metabolite-driven vulnerability: suppressing TPI1, or pharmacologically reinforcing the SARM1-cADPR-calcium-mtROS cascade it controls, might push tumors into senescence deliberately, potentially priming them for immune clearance, while calcium chelation or cADPR antagonism could protect vulnerable tissues. The authors caution that the sensor connecting DHAP to SARM1 remains unidentified, that rapamycin only partially suppressed the phenotype, and that whether the cascade is fully reversible is unknown. Still, the conceptual shift is hard to miss: a century after glycolysis was first mapped in tumors, one of its smallest intermediates has turned out to be a messenger—and cancer cells, it seems, listen closely.

Subject of Research: Metabolite-driven mitochondrial redox signaling linking TPI1 loss to cellular senescence via the SARM1–cADPR–Ca2+ axis in cancer

Article Title: TPI1 Loss Triggers a Metabolite‐Driven Mitochondrial Redox Vulnerability via the SARM1–cADPR–Ca2+ Axis

Article References: Liu, C., Wu, S., Wang, C., Zhou, Z., Cai, T., Tao, W., Zuo, S., Zhang, C., Dong, Y., Feng, Y., Huang, Q., Wang, B., Ma, X., Ma, H., Zhang, X., & Huang, Y. (2026). TPI1 Loss Triggers a Metabolite‐Driven Mitochondrial Redox Vulnerability via the SARM1–cADPR–Ca 2+ Axis. Advanced Science, 13(56), Article e76614. https://doi.org/10.1002/advs.76614

Image Credits: AI Generated

DOI: 10.1002/advs.76614

Keywords: TPI1, DHAP, SARM1, cADPR, calcium signaling, mitochondrial ROS, cellular senescence, clear cell renal cell carcinoma, CRISPR screen, glycolysis, p53-p21 pathway, mTORC1

The finding rests on a deceptively simple biological insight. Cancer cells are addicted to nucleotides, the raw material of DNA and RNA, and they ramp up ribonucleotide production by 6 to 11-fold compared with normal proliferating cells to fuel their relentless division, metastasis, and drug resistance. But this hyperactive metabolism creates a vulnerability: when the balance between ribonucleotides and deoxyribonucleotides is thrown off, mitochondria become stressed, and their DNA — normally sealed inside these energy-producing organelles — leaks into the cytosol. The innate immune sensor cGAS recognizes this misplaced DNA and activates the STING pathway, prompting the cancer cell to pump out type I interferons and recruit the immune system against itself.

Fluoropyrimidines already exploit this logic in part. As antimetabolites, they disrupt nucleotide synthesis, damage DNA, and can ignite cGAS–STING signaling. Yet their clinical power has long been blunted by two problems: they are metabolically unstable, and they must compete with the supraphysiological pools of endogenous nucleotides that cancer cells maintain. Despite decades of optimization — enzyme inhibitors, the prodrug capecitabine, the S-1 regimen, trifluridine-tipiracil — outcomes in advanced colorectal cancer, which kills roughly 700,000 people each year, remain stubbornly poor. The Nanjing University-led team hypothesized that rather than fighting the tumor’s nucleotide surplus, they could weaponize it.

Through systematic screening of nucleotide combinations with floxuridine, they discovered that pyrimidine ribonucleotides — especially CMP — transformed the drug’s activity. The synergy was strikingly specific: CMP alone did nothing, and it barely enhanced the widely used drug 5-fluorouracil or its metabolite fluorouridine. Only floxuridine and its active metabolite FdUMP, which feed directly into deoxyribonucleotide metabolism, responded. This selectivity traces to metabolic partitioning: 5-fluorouracil preferentially enters RNA metabolism, while floxuridine is channeled toward FdUMP, the molecule that covalently inhibits thymidylate synthase, the enzyme that makes the essential DNA building block TMP.

CRISPR–Cas9 library screening revealed exactly which enzymes were holding floxuridine back. Five pyrimidine metabolism genes — CMPK1, CMPK2, TYMP, UPP1, and UPP2 — emerged as the top hits that, when lost, made cells more sensitive to the drug. Analyzing over 4,700 patient samples from The Cancer Genome Atlas, the team showed that patients whose tumors expressed low levels of these five genes survived significantly longer, underscoring their clinical relevance. Remarkably, CMP and its intracellular metabolites, including uridine and 2′-deoxyuridine, were able to engage all five enzymes simultaneously, as demonstrated by drug affinity responsive target stability assays. No existing small-molecule inhibitor achieves this multi-target blockade, and developing one would be costly and unpredictable.

The metabolic consequences were dramatic. Liquid chromatography–tandem mass spectrometry showed that CMP boosted peak intracellular FdUMP levels nearly 500-fold and extended the metabolite’s half-life from 0.14 hours to 3.45 hours — a more than 20-fold increase in persistence. Cellular thermal shift assays confirmed that the accumulated FdUMP bound and stabilized thymidylate synthase more effectively, deepening the blockade of TMP synthesis. When the team supplemented cells with TMP itself, the synergy vanished entirely, proving the mechanism runs through thymineless death rather than direct interference with DNA replication. Purine nucleotides, by contrast, were cytotoxic at high concentrations and offered no benefit.

Depleted TMP synthesis triggered exactly the mitochondrial crisis the researchers predicted. Quantitative PCR along the mitochondrial genome revealed a position-dependent gradient of copy-number loss spreading from the replication origin — a molecular fingerprint of stalled replication forks. Damaged mitochondrial DNA then escaped into the cytosol, largely through VDAC1 channels: blocking VDAC1 oligomerization with the inhibitor VBIT-4 suppressed the interferon response just as effectively as depleting mitochondrial DNA altogether. Pharmacological inhibition of cGAS with RU.521 or of STING with H-151 likewise shut down the signal, and tumors grew poorly in response to the combination only in mice with functional STING.

Translating the chemistry into a clinic-ready formulation required solving a delivery dilemma. CMP and FdUMP are both highly hydrophilic, poorly permeable molecules, and the synergy collapsed when dosing intervals exceeded two hours — evidence that the two must be metabolized inside the same cell at the same time. The team exploited metal coordination chemistry, discovering that ferric iron could bridge the phosphate groups of CMP and FdUMP into self-assembling nanoscale coordination polymers. Wrapped in a PEGylated lipid shell, the resulting FC-NPs measured roughly 107 nanometers, remained stable in the bloodstream, and released their payload only in the acidic environment of endosomes, achieving true synchronized co-delivery.

In mouse models of colorectal cancer, the nanoparticles delivered on their promise. Three intratumoral injections of FC-NPs inhibited MC38 tumor growth by 82 percent, compared with just 31 percent for the free drug mixture, while cutting the required dosing frequency from thrice daily to once daily. Treated tumors flooded with IFN-β, CXCL10, TNF-α, and IFN-γ, and produced markedly more tumor antigen-specific CD8-positive T cells. The efficacy vanished in mice lacking cross-presenting dendritic cells or depleted of CD8-positive T cells, confirming that adaptive antitumor immunity — the downstream product of STING activation — was the engine of the response. Most strikingly, adding anti-PD-L1 antibody to the nanoparticles produced complete tumor rejection in all treated mice, a result neither therapy achieved alone. Because floxuridine is already the standard agent for hepatic artery infusion in colorectal liver metastases, the authors argue that co-delivering CMP in that regional setting offers a direct, actionable path to the clinic, with CMP showing good biosafety in vivo.

Subject of Research: A metabolic strategy in which ribonucleotides amplify fluoropyrimidine-induced mitochondrial DNA release and cGAS–STING activation to potentiate colorectal cancer chemoimmunotherapy

Article Title: Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy

Article References: Wang, C., Zhao, C., Yao, Y., Zou, Z., Shi, A., Feng, Z., Yang, M., Yu, Y., Liu, Y., Rui, X., & Wu, J. (2026). Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy. Advanced Science, Article e77614. https://doi.org/10.1002/advs.77614

Image Credits: AI Generated

DOI: 10.1002/advs.77614

Keywords: cGAS–STING, mitochondrial DNA, ribonucleotides, floxuridine, colorectal cancer, chemoimmunotherapy, lipid nanoparticles, nucleotide metabolism, FdUMP, thymidylate synthase, PD-L1 blockade, CRISPR screen

The researchers began with an unbiased approach designed to let the cells themselves point to the answer. Using a genome-wide CRISPR screen, they systematically disabled every gene in human cells and then flooded the survivors with high levels of cysteine. If a cell lacking a particular gene suddenly became resistant to cysteine’s lethal effects, that gene was likely part of the killing machinery. The screen delivered a striking and somewhat counterintuitive result: the strongest protective hits were not antioxidant enzymes or detoxification pathways, but the mitochondrial iron transporters SLC25A28 and SLC25A37, also known as mitoferrins. These proteins sit in the inner mitochondrial membrane and shuttle iron into the organelle. When the researchers knocked them out, cells tolerated cysteine doses that would otherwise be fatal, indicating that the import of iron into mitochondria is an essential step in cysteine toxicity.

That finding reframed the problem entirely. Rather than acting as a simple chemical toxin that oxidizes or alkylates cellular components, excess cysteine appears to hijack the cell’s own iron logistics. The team showed that limiting mitochondrial iron availability suppresses cysteine-induced cell death and, crucially, prevents the damage that cysteine inflicts on iron–sulfur cluster proteins and on respiration itself. Iron–sulfur clusters are tiny cofactors assembled inside mitochondria and installed into a wide range of proteins, including components of the respiratory chain that generate cellular energy and enzymes that maintain the genome. When their integrity fails, mitochondria falter, energy production collapses, and the cell begins to die.

To understand how a surplus of an amino acid could destabilize iron in the first place, the researchers traced the metal’s movements through the cell. Their experiments revealed that cysteine mobilizes iron from ferritin, the cell’s principal iron storage cage, expanding the cytosolic pool of freely available iron. That liberated iron is then driven into mitochondria through the mitoferrin transporters, causing the organelles to accumulate iron to dangerous levels. This mechanism echoes classical biochemistry: reductants, including thiols, have been known since the 1970s to release iron from ferritin, and in bacteria, high intracellular cysteine was shown more than twenty years ago to promote oxidative DNA damage by fueling the Fenton reaction, in which iron converts hydrogen peroxide into destructive hydroxyl radicals. The new work shows that in human cells, the consequences of this iron release converge specifically on mitochondria.

Why would extra iron inside mitochondria be so lethal? The answer, according to the study, lies in the delicate redox chemistry of the organelle. The researchers found that the balance between reduced and oxidized glutathione, the cell’s master antioxidant couple, becomes critically imbalanced downstream of iron accumulation. Mitochondria normally maintain a robust pool of reduced glutathione, imported through the transporter SLC25A39, to buffer the reactive chemistry of the respiratory chain. When cysteine overload disrupts this balance, iron–sulfur cluster proteins begin to deteriorate, including respiratory chain components and mitochondrial translation factors that depend on these clusters. Proteomic analysis confirmed that cysteine treatment selectively depletes iron–sulfur cluster-containing proteins from the mitochondrial compartment, and respiration measurements showed corresponding losses of basal and maximal oxygen consumption.

The most elegant experiment in the paper demonstrates that this redox collapse is not merely a side effect but a causal driver of death. The researchers engineered cells to express a bacterial enzyme, GshF, that synthesizes glutathione, targeting it either to the cytosol or specifically to mitochondria. Boosting glutathione reductase activity within mitochondria alone restored redox balance downstream of iron accumulation and protected cells from cysteine toxicity by preserving iron–sulfur cluster integrity. Cytosolic glutathione enhancement, by contrast, offered far less protection. In other words, the battle over life and death is fought inside the mitochondrial matrix, where the glutathione pool must keep pace with the iron-driven chemical storm that excess cysteine ignites.

The study also clarifies how this newly defined death pathway differs from the better-known forms of regulated cell death. Ferroptosis, discovered in 2012, occurs when cysteine depletion lowers glutathione, inactivating the lipid-repair enzyme GPX4 and allowing iron-dependent lipid peroxidation to shred cellular membranes. Disulfidptosis, described in 2023, arises under glucose starvation when high cysteine levels promote aberrant disulfide bonds in actin cytoskeleton proteins. The pathway described by Nakamura and colleagues is mechanistically distinct: it requires mitochondrial iron import, proceeds through ferritin mobilization and glutathione redox imbalance, and culminates in the loss of iron–sulfur clusters rather than lipid peroxidation or cytoskeletal collapse. The authors propose that this represents a distinct mitochondrial iron-dependent cell death triggered under conditions of thiol imbalance.

The findings carry weight well beyond basic cell biology. Cells keep their cysteine levels remarkably low, a fact that has long hinted at the molecule’s intrinsic toxicity, and the new work explains why: maintaining low cysteine safeguards mitochondrial iron homeostasis. That principle has clinical echoes. Elevated plasma cysteine has been associated with vascular disease and is disturbed in cirrhosis, and recent studies have shown that cysteine depletion can drive dramatic weight loss by triggering adipose tissue thermogenesis, while dietary cysteine influences intestinal stemness through immune signaling. Cancer adds another layer of relevance. Some tumors, particularly those with NRF2 activation, appear vulnerable to excess cysteine through conjugate formation, and D-cysteine has been shown to impair tumor growth by inhibiting the iron–sulfur cluster assembly enzyme NFS1. A therapy that deliberately pushes cysteine above toxic thresholds, or that blocks mitochondrial glutathione reduction to sensitize cells to thiol stress, could exploit this newly mapped vulnerability.

There are also implications for aging. Earlier work from the same scientific lineage showed that cysteine toxicity drives age-related mitochondrial decline by altering iron homeostasis, and the new mechanistic framework gives that observation a concrete molecular basis: ferritin mobilization, mitoferrin-mediated iron import, and glutathione redox failure inside mitochondria. As organisms age, mitochondrial iron handling becomes increasingly error-prone, and thiol metabolism shifts in ways that could tip vulnerable cells toward this death pathway. Understanding the checkpoints along that route, from ferritin release to SLC25A28 and SLC25A37 activity to mitochondrial glutathione reductase capacity, offers a series of potential intervention points.

What makes the study especially compelling is its demonstration that a nutrient’s protective and poisonous faces are governed by the same underlying chemistry. Cysteine supports iron–sulfur cluster biogenesis when dosed correctly and dismantles it when dosed in excess, with the difference determined by how much iron the mitochondria admit and how much reducing power they retain. The Rockefeller-led team has thus turned a decades-old puzzle into a coherent mechanism, one that connects amino acid metabolism, metal trafficking and redox biology into a single lethal circuit. As researchers now test whether this mitochondrial iron-dependent death operates in tissues and diseases where thiol levels run high, the humble amino acid that every biology student learns to love may gain a reputation as one of the cell’s most dangerous tenants when it overstays its welcome.

Subject of Research: Mechanism of cysteine-induced mitochondrial iron-dependent cell death

Article Title: Cysteine excess triggers a mitochondrial iron-dependent cell death

Article References: Nakamura, T., Inoki, A., Das, N. K., Chen, B., Khan, A., Liu, Y., Uygur, B., Yen, F. S., Unlu, G., Shah, Y. M., & Birsoy, K. (2026). Cysteine excess triggers a mitochondrial iron-dependent cell death. Nature Metabolism. https://doi.org/10.1038/s42255-026-01616-7

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01616-7

Keywords: cysteine, mitochondria, iron homeostasis, cell death, iron–sulfur clusters, glutathione, ferritin, mitoferrin, ferroptosis, redox balance, metabolism, CRISPR screen

The method, described in the journal BMC Bioinformatics by Jack Kamm, Jake Yeung, and William F. Forrest of Genentech, reframes guide assignment as a problem in classical statistics. Rather than fitting an elaborate probabilistic model to the guide count matrix, the authors propose treating the matrix of guide RNA counts across cells as a contingency table. For every cell-guide pair, they construct a two-by-two table that contrasts the counts involving that cell and that guide with all other counts, and then apply Fisher’s Exact Test, a workhorse of categorical data analysis, to ask whether the cell and guide barcodes are statistically associated. A significant association signals that the guide is genuinely present in the cell rather than appearing by chance through sequencing noise.

The elegance of this formulation lies in what it provides automatically. Because Fisher’s Exact Test conditions on the margins of the contingency table, the resulting p-values implicitly normalize for both cell-specific and guide-specific size factors, the uneven sequencing depth that plagues single-cell data. Cells that received more total reads and guides that were more abundant in the library are handled without any explicit normalization step. The method also produces a p-value for every cell-guide pair, giving users a graded measure of confidence rather than a hard binary call, and enabling downstream analyses such as full precision-recall curves when benchmarking alternative cutoffs.

Two statistical subtleties demanded additional innovation. First, because the method performs one test for every cell-guide combination, large screens can involve tens of millions of hypothesis tests. Naive application of standard multiple testing corrections such as the Benjamini-Hochberg procedure would be inappropriate, because the tests are strongly correlated: a cell that tests positive for one guide is less likely to test positive for others, and counts involving the same guide or the same cell share information. The authors developed a multiple testing correction strategy that accounts for this correlation structure, preserving control of the false discovery rate while avoiding the excessive conservatism that would come from ignoring the dependencies.

The second subtlety is a form of confounding that can flip conclusions in exactly the wrong way. Ambient RNA contamination, sometimes called soup or background noise, introduces guide molecules into cells that never received them. If the contamination is not independent across cells and guides, a phenomenon analogous to Simpson’s paradox can arise: an association that appears significant in the aggregate data disappears, or even reverses, once the noise component is considered separately. Fishash addresses this by testing an adjusted odds ratio that replaces the margins involving the focal cell and guide with their noise-based counterparts. To estimate the unobserved noise counts, the method performs an iterative rank-1 Poisson matrix completion: entries that have already been confidently assigned are masked out, the remaining background structure is fit under a Poisson likelihood by alternating updates of guide and cell abundance parameters, and the imputed noise counts feed back into refined p-values. The procedure repeats until the assignments stabilize.

Recognizing that fair comparison of guide assignment methods has been hampered by a lack of realistic test data, the authors also introduced a simulation framework that generates synthetic guide counts under a detailed model of sequencing noise. The simulator draws on the contamination model popularized by the Cellbender software, incorporating latent cell-level factors such as ambient RNA fractions, capture efficiencies, and dropout rates, along with guide-level expression variation. Crucially, the simulations can vary the number of guides in the library and the multiplicity of infection, the average number of guides delivered per cell, allowing benchmarking across the parameter regimes that matter in practice. The code to reproduce all results is publicly available alongside the method itself.

In benchmarks on both simulated and real datasets, Fishash compared favorably with existing approaches in both accuracy and runtime. On simulations varying the number of guides, the method achieved the top median F1 score in the majority of settings, performing particularly well when the guide library was large or guide RNA expression was low. In simulations varying the multiplicity of infection, Fishash remained competitive at low multiplicity, where most cells carry at most one guide, though other methods such as crispat-NB and dcCLEANSER edged ahead at high multiplicity. The authors emphasize that Fishash was conservative in its error control: its observed precision stayed above its nominal lower bound across the sweep, whereas several competing Bayesian and frequentist methods failed to control the false discovery rate at least once across the scenarios tested.

The stress tests also revealed the method’s limits, which the authors report transparently. When extra overdispersion was injected into the noise counts by replacing the Poisson distribution with a Geometric distribution, one of the most extreme overdispersion regimes available, precision dropped for many methods and Fishash no longer controlled the false discovery rate at its nominal five percent level in every scenario. Even so, its F1 scores remained qualitatively similar to the original benchmarks, indicating a competitive balance between precision and recall even under unusually harsh noise. The authors note that the conditional low-rank Poisson structure assumed for background counts is common to many single-cell contamination models, including Cellbender, SoupX, DecontX, and scAR, so the simulation represents a deliberately challenging departure from the assumptions shared across the field.

Practical accessibility was a design priority. Fishash is distributed as an easy-to-use R package on GitHub, and because it relies on exact tests over contingency tables rather than iterative model fitting, it scales comfortably to screens with tens of thousands of cells and guides, where computationally expensive probabilistic approaches can become prohibitive. The software also outputs its test statistic for every entry of the cell-guide matrix, which allows users to visualize the distribution of scores, select alternative significance cutoffs informed by the data, and compute full precision-recall curves during method benchmarking. The work was carried out entirely within Genentech, with the authors crediting colleagues in the company’s AI Biology and Translation department for discussions that shaped the manuscript.

For the growing community running Perturb-seq experiments, the significance of the method is straightforward: guide assignment is the gatekeeper step that determines whether downstream perturbation effects are real or artifacts of misassignment, and errors made here propagate through every subsequent analysis. By combining a classical, well-understood statistical test with modern corrections for multiplicity, confounding, and background contamination, and by packaging the result in fast, open software, Fishash lowers both the computational and conceptual barriers to reliable pooled single-cell screening. As CRISPR screens continue to expand in scale and ambition, tools that trade heavy model fitting for careful, assumption-aware statistics are likely to play an increasingly central role in turning raw sequencing counts into trustworthy biological conclusions.

Subject of Research: A contingency table and Fisher's Exact Test based method for assigning guide RNAs to cells in single-cell pooled CRISPR screens (Perturb-seq)

Article Title: Fishash: a contingency table approach to Perturb-seq guide assignment

Article References: Kamm, J., Yeung, J., & Forrest, W. F. (2026). Fishash: a contingency table approach to Perturb-seq guide assignment. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06631-9

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06631-9

Keywords: Perturb-seq, CRISPR screen, single-cell RNA-seq, guide assignment, Fisher's exact test, Simpson's paradox, multiple testing correction, contingency table, false discovery rate, ambient RNA contamination, functional genomics, BMC Bioinformatics

The study began with a practical problem: researchers have lacked good tools to study the behavior of hepatitis B virus-specific T cells in a physiologically relevant setting. The team used a humanized mouse model carrying the human HLA-A11 molecule to identify a T cell receptor that recognizes HBc141-151, an epitope from the hepatitis B core antigen that is clinically relevant in human patients. This receptor, which the authors call HB-I, allowed them to generate transgenic mice whose entire CD8+ T cell population is specific for a single, human-relevant HBV epitope, providing a tractable platform for dissecting why these cells fail during chronic infection.

With that platform in hand, the researchers turned to an unbiased discovery strategy. Using a whole-genome CRISPR-Cas9 knockout library delivered into HBV-specific T cells, followed by screening under chronic antigen stimulation, they asked which genes, when deleted, would help T cells resist the dysfunctional state that normally develops. The screen converged on Ankrd11, a gene previously known as a chromatin regulator implicated in neural development and in Kabuki-like syndromes, but never before linked to T cell exhaustion. Loss of Ankrd11 consistently produced T cells that proliferated more vigorously and retained stronger effector characteristics.

The mechanistic picture that emerges from the paper is epigenetic. ANKRD11 appears to restrain the accessibility and acetylation of key effector genes. Using ATAC-seq, bulk RNA-seq and CUT&Tag profiling of the histone mark H3K27ac, the team showed that Ankrd11-deficient CD8+ T cells display increased chromatin openness and enhancer acetylation at loci encoding AP-1 family transcription factors, notably Fos and Fosb. Elevated AP-1 activity, in turn, drives a program of effector differentiation: the cells produce more granzyme B and interferon-gamma, resist the immunosuppressive conditions that normally silence them, and maintain function even when interleukin-2, a survival factor, is limiting.

Functionally, the consequences of losing this brake were striking. In mice carrying a replicating HBV plasmid or infected with recombinant HBV vectors, Ankrd11-deficient HBV-specific T cells expanded more robustly, infiltrated the liver more effectively, and drastically reduced serum levels of hepatitis B surface antigen, viral DNA and markers of liver damage. Parallel experiments using a second chronic infection model, lymphocytic choriomeningitis virus clone 13, confirmed the generality of the effect: adoptively transferred Ankrd11-deficient virus-specific P14 T cells showed enhanced granzyme expression, proliferation and viral control in the spleen and blood.

Perhaps the most conceptually interesting finding concerns the differentiation paths that exhausted T cells normally follow. In chronic infection and cancer, antigen-specific CD8+ T cells split into progenitor exhausted T cells, which express the transcription factor TCF-1 and serve as a self-renewing reservoir, and terminally exhausted T cells, which lose TCF-1 and are irreversibly dysfunctional. The authors found that Ankrd11 deficiency accelerates the conversion of progenitor exhausted cells into effector-like exhausted cells, but importantly, the resulting cells are cytotoxic and functional rather than inert. This suggests ANKRD11 does not simply maintain progenitor pools but actively gates how far exhausted cells differentiate toward effector competence.

The study also revealed a distinct route of reprogramming specific to chronic hepatitis B. A large fraction of HBV-specific CD8+ T cells in tolerant mice carries a PD-1-negative, TOX-negative phenotype that has resisted conventional checkpoint-based rescue strategies. When ANKRD11-mediated repression was relieved, these tolerant cells differentiated into PD-1-positive, KLRG1-positive effector cells armed with high granzyme levels, providing an explanation for the improved viral clearance. In other words, ANKRD11 deficiency unlocks an otherwise dormant pool of virus-specific cells that immune checkpoint blockade alone cannot reach.

The antitumor implications were tested directly in cancer models. Ankrd11-deficient CD8+ T cells promoted rejection of implanted tumors, enhanced intratumoral T cell activity, and acted synergistically with immune checkpoint blockade, potentiating the effect of PD-1 pathway inhibition. Given that the exhaustion of tumor-infiltrating lymphocytes is a central cause of immunotherapy failure, a single gene whose deletion reprograms effector differentiation under immunosuppressive conditions is an attractive candidate for therapeutic engineering, for example in chimeric antigen receptor or T cell receptor-engineered cell products. A provisional patent application has been filed based on the findings, underscoring the translational interest.

Caveats remain before ANKRD11 targeting reaches the clinic. ANKRD11 is a broad chromatin regulator with established roles in neural and cardiac development, so systemic inhibition is unlikely to be safe; the therapeutic window will probably lie in ex vivo engineering of T cells or in carefully targeted delivery. It will also be important to determine whether accelerated terminal differentiation comes at the cost of long-term memory formation. Nevertheless, the study delivers a clear conceptual advance: T cell dysfunction in chronic infection and cancer is not merely the product of inhibitory receptor signaling, but is epigenetically authored, and specific chromatin factors such as ANKRD11 can be removed to rewrite that script. For the hundreds of millions of people living with chronic hepatitis B, and for cancer patients whose T cells have gone quiet, that insight opens a new direction for immunotherapy design.

The concept of T cell exhaustion has shaped immunology for two decades. Since the landmark demonstration that chronically stimulated CD8+ T cells can regain function when inhibitory pathways are interrupted, researchers have catalogued a molecular signature of the dysfunctional state, and later work established the transcription factor TOX as a master architect of the exhaustion program, acting at both transcriptional and epigenetic levels. What has remained less clear is whether exhaustion is a fixed fate or a tunable state whose chromatin underpinnings can be deliberately rewritten. The new study adds weight to the second view by identifying a specific chromatin-associated protein whose removal shifts the balance of differentiation toward cytotoxic competence.

The methodological route to this finding is worth noting. Genome-wide CRISPR-Cas9 knockout screens have become a powerful way to uncover genes that constrain or enable T cell behavior, and previous efforts using this approach identified regulators such as REGNASE-1 and Roquin as suppressors of effector expansion and antitumor immunity. The present screen extends this logic into the setting of chronic hepatitis B virus infection, a context in which suppressive cues differ from those in tumors and in which conventional checkpoint blockade has shown only modest clinical benefit. That an unbiased screen converged on a gene with no prior immunological pedigree illustrates how phenotype-first discovery can bypass assumptions rooted in known pathways.

ANKRD11 itself carries an interesting dual history. It was first characterized as a chromatin regulator essential for neural development, and subsequent work showed it controls cardiac neural crest-mediated remodeling of the outflow tract. Its association with a Kabuki-like syndrome in humans reflects the pleiotropic consequences of disturbing a factor that operates broadly across tissues. This background both explains why the protein had escaped attention in immunology and reinforces the caution that any therapeutic interference must be confined to engineered cells rather than delivered systemically.

The AP-1 connection provides a mechanistic bridge to earlier T cell biology. AP-1 family transcription factors, built from Fos and Jun proteins, have long been recognized as immediate-early responders to T cell receptor signaling, and their activity is known to cooperate with other factors to specify effector genes. By showing that ANKRD11 restrains chromatin accessibility and H3K27 acetylation at AP-1 loci, the study suggests a route by which a chromatin regulator can gate a transcriptional program that is otherwise primed and waiting in naive and exhausted cells alike.

The authors have deposited the datasets underlying these conclusions in public repositories: bulk RNA-seq data under accession GSE299520, ATAC-seq data under GSE299519, and CUT&Tag data under GSE299521, with source data provided alongside the paper. No original code was generated. This transparency should allow groups working on T cell engineering to interrogate the chromatin changes directly and to test whether similar ANKRD11-sensitive programs operate in human tumor-infiltrating lymphocytes, a necessary step before the findings can inform next-generation cell therapy design.

Subject of Research: Epigenetic regulation of CD8+ T cell dysfunction in chronic viral infection and cancer

Article Title: ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer

Article References: Xu, W., Guo, J., Cao, X., Li, L., Xiao, P., Zhang, X., Jin, Q., Zhang, F., Hou, B., Li, M., & Zhou, X. (2026). ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer. Nature Immunology. https://doi.org/10.1038/s41590-026-02652-x

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02652-x

Keywords: ANKRD11, CD8+ T cells, T cell exhaustion, chronic hepatitis B, epigenetics, immunotherapy, CRISPR screen, AP-1 transcription factors, granzyme B, immune checkpoint blockade, tumor immunity, T cell receptor